AVR 0.00% $18.00 anteris technologies ltd

Ann: Admedus announces further data from HSV-2 Trial, page-82

  1. 819 Posts.
    lightbulb Created with Sketch. 3
    Similar response? LOL
    1 is 50%, the others didn't even say anything, but with lesion rate of ~40%, the last one is not in phase 1 yet.

    We are in phase 1, a bit slower than the first company which is in phase 2. We have 95% (albeit small sampling size), they have 50%.
    I don't know, looks pretty good to me. Similar? Not even close.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.